Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Capital Expenditures (2020 - 2025)

Barinthus Biotherapeutics' Capital Expenditures history spans 6 years, with the latest figure at $37000.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures fell 80.73% year-over-year to $37000.0; the TTM value through Dec 2025 reached $37000.0, down 95.85%, while the annual FY2025 figure was $37000.0, 95.85% down from the prior year.
  • Capital Expenditures reached $37000.0 in Q2 2025 per BRNS's latest filing, down from $278000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.9 million in Q4 2022 to a low of -$2.9 million in Q3 2022.
  • Average Capital Expenditures over 5 years is $801529.4, with a median of $278000.0 recorded in 2024.
  • The largest YoY upside for Capital Expenditures was 3703.51% in 2022 against a maximum downside of 511.1% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $424000.0 in 2021, then soared by 1295.99% to $5.9 million in 2022, then tumbled by 102.58% to -$153000.0 in 2023, then surged by 281.7% to $278000.0 in 2024, then plummeted by 86.69% to $37000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Capital Expenditures are $37000.0 (Q2 2025), $278000.0 (Q4 2024), and $114000.0 (Q3 2024).